GGrantIndex
← Leaderboards

Joanna M Biernacka

Mayo Clinic Rochester

$6,043,821
Attributed
$8,737,247
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,737,247 · 7

By mechanism

R01$4,196,272 · 3
U01$3,676,343 · 1
R21$789,460 · 2
R03$75,172 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Genome Wide Association Study

Research focus

Genome Wide Association StudyGeneticGenome-WidePhenotypeSamplingResponseGenesVariantHeritabilityBasePathway InteractionsGenetic VariationGenetic AssociationAlcohol Use DisorderTreatment OutcomeTreatment ResponseClinical DataGenetic MarkersSubstance Use DisorderPharmacogenomicsSelection For TreatmentsTraitPharmaceutical PreparationsCandidate Disease Gene

Grant awards (23)

6/7 PsycheMERGE: Advancing Precision Psychiatry$442,460
R01 · FY2025 · MH · contact PI
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$374,995
R01 · FY2025 · AA
6/7 PsycheMERGE: Advancing Precision Psychiatry$436,004
R01 · FY2024 · MH · contact PI
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disorders$404,531
R01 · FY2024 · MH · contact PI
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$369,593
R01 · FY2024 · AA
Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines$548,545
R01 · FY2023 · AA
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disorders$405,339
R01 · FY2023 · MH · contact PI
Pharmacogenomics of Acamprosate Treatment Outcome (Supplement)$155,616
U01 · FY2023 · AA
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$416,055
U01 · FY2022 · AA
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$676,116
U01 · FY2021 · AA
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disorders$405,409
R01 · FY2021 · MH · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$719,820
U01 · FY2020 · AA
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disorders$404,741
R01 · FY2020 · MH · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$754,148
U01 · FY2019 · AA
2/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disorders$404,655
R01 · FY2019 · MH · contact PI
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$190,678
U01 · FY2019 · AA
PHARMACOGENOMICS OF ACAMPROSATE TREATMENT OUTCOME$763,910
U01 · FY2018 · AA
Pharmacogenomics of Treatment Outcomes in Alcohol Use Disorders$149,063
R21 · FY2017 · AA · contact PI
Pharmacogenomics of Treatment Outcomes in Alcohol Use Disorders$268,313
R21 · FY2016 · AA · contact PI
Methods for detecting interacting risk factors for addictions$183,209
R21 · FY2011 · DA · contact PI
Methods for detecting interacting risk factors for addictions$188,875
R21 · FY2010 · DA · contact PI
Pathway-based analysis of addiction susceptibility genes$37,397
R03 · FY2010 · AA · contact PI
Pathway-based analysis of addiction susceptibility genes$37,775
R03 · FY2009 · AA · contact PI